The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting a strategic pivot toward its core business, ResMed has announced the sale of its MatrixCare unit for $490 million. This divestiture is designed to sharpen the company's focus on the sleep health sector, prioritizing long-term growth in its primary markets over non-core software assets. According to reports, while the deal streamlines the corporate portfolio, it is expected to introduce some near-term dilution to earnings per share.
This strategic reset occurs as healthcare technology firms increasingly prioritize specialized medical hardware over broad software services. Compared to its peers, ResMed has maintained robust margins in respiratory care, though major investment banks including JPMorgan and Citi recently lowered their price targets for the stock (per market data and analyst reports) citing concerns over shifting digital health demand.
Shares of RMD closed at $208.45 (as of July 9, 2026), having traded between a day low of $205 and a high of $209.33. Investors are now watching for how effectively the company can offset the expected EPS dilution through accelerated sales in its core sleep categories. Looking ahead, market participants will monitor upcoming US ISM Services PMI data for broader signals on operating costs and domestic demand.